Enorama Pharma AB (publ) (ERMA.ST)
SEK 2.95
(3.15%)
SEK 2.95
(3.15%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.35 Million SEK | -80.17% |
| 2022 | 6.84 Million SEK | -37.96% |
| 2021 | 11.03 Million SEK | 414.26% |
| 2020 | 2.14 Million SEK | -71.8% |
| 2019 | 7.61 Million SEK | 44.8% |
| 2018 | 5.25 Million SEK | 234.16% |
| 2017 | 1.57 Million SEK | -60.59% |
| 2016 | 3.99 Million SEK | 100.18% |
| 2015 | 1.99 Million SEK | 44.14% |
| 2014 | 1.38 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 5.65 Million SEK | 56660.0% |
| 2024 Q1 | -10 Thousand SEK | -105.81% |
| 2023 Q1 | 678 Thousand SEK | 2018.75% |
| 2023 Q3 | 51 Thousand SEK | -88.84% |
| 2023 Q2 | 457 Thousand SEK | -32.6% |
| 2023 FY | 1.35 Million SEK | -80.17% |
| 2023 Q4 | 172 Thousand SEK | 237.25% |
| 2022 Q3 | 3.9 Million SEK | 35.73% |
| 2022 Q4 | 32 Thousand SEK | -99.18% |
| 2022 FY | 6.84 Million SEK | -37.96% |
| 2022 Q1 | 49 Thousand SEK | -98.94% |
| 2022 Q2 | 2.87 Million SEK | 5765.31% |
| 2021 Q3 | 1.42 Million SEK | -55.81% |
| 2021 FY | 11.03 Million SEK | 414.26% |
| 2021 Q4 | 4.62 Million SEK | 225.55% |
| 2021 Q1 | 1.77 Million SEK | 132.44% |
| 2021 Q2 | 3.21 Million SEK | 80.98% |
| 2020 FY | 2.14 Million SEK | -71.8% |
| 2020 Q2 | 4.46 Million SEK | 46.7% |
| 2020 Q1 | 3.04 Million SEK | 357.79% |
| 2020 Q3 | 116 Thousand SEK | -97.4% |
| 2020 Q4 | -5.47 Million SEK | -4821.55% |
| 2019 Q3 | 2.34 Million SEK | -44.25% |
| 2019 Q4 | 664.71 Thousand SEK | -71.69% |
| 2019 FY | 7.61 Million SEK | 44.8% |
| 2019 Q1 | 386 Thousand SEK | -65.26% |
| 2019 Q2 | 4.21 Million SEK | 991.19% |
| 2018 Q2 | 1.67 Million SEK | 1.95% |
| 2018 FY | 5.25 Million SEK | 234.16% |
| 2018 Q4 | 1.11 Million SEK | 33.37% |
| 2018 Q3 | 833 Thousand SEK | -50.15% |
| 2018 Q1 | 1.63 Million SEK | 4.2% |
| 2017 Q3 | 395 Thousand SEK | -83.14% |
| 2017 Q1 | 584 Thousand SEK | 577.46% |
| 2017 Q2 | 2.34 Million SEK | 301.2% |
| 2017 FY | 1.57 Million SEK | -60.59% |
| 2017 Q4 | 1.57 Million SEK | 298.2% |
| 2016 Q1 | 1.41 Million SEK | -29.18% |
| 2016 FY | 3.99 Million SEK | 100.18% |
| 2016 Q4 | 86.2 Thousand SEK | -94.26% |
| 2016 Q3 | 1.5 Million SEK | 51.56% |
| 2016 Q2 | 991 Thousand SEK | -29.82% |
| 2015 FY | 1.99 Million SEK | 44.14% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q4 | 1.99 Million SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2014 FY | 1.38 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 1.29 Billion SEK | 99.895% |
| Enzymatica AB (publ) | 50.9 Million SEK | 97.332% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | - SEK | -Infinity% |
| Nanexa AB (publ) | 29.32 Million SEK | 95.369% |
| Newbury Pharmaceuticals AB (publ) | 36.82 Million SEK | 96.313% |
| ODI Pharma AB | 22.44 Million SEK | 93.95% |
| Orexo AB (publ) | 638.8 Million SEK | 99.787% |
| Probi AB (publ) | 627.68 Million SEK | 99.784% |
| Swedencare AB (publ) | 2.32 Billion SEK | 99.942% |
| Swedish Orphan Biovitrum AB (publ) | 22.12 Billion SEK | 99.994% |
| Toleranzia AB | 50.92 Million SEK | 97.333% |
| Vivesto AB | 1.01 Million SEK | -33.793% |